scholarly journals Clinical effects of nursing intervention for soothing liver and regulating Qi in diarrhea-type irritable bowel syndrome patients with Qi stagnation constitution

2017 ◽  
Vol 25 (4) ◽  
pp. 374
Author(s):  
Yuan-Ying Mao
Keyword(s):  
Irritable Bowel Syndrome ◽  
Nursing Intervention ◽  
Clinical Effects ◽  
Qi Stagnation ◽  
Irritable Bowel

scholarly journals Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review

2020 ◽  
Vol 13 ◽  
pp. 175628481989753 ◽  
Author(s):  
William D. Chey ◽  
Eric D. Shah ◽  
Herbert L. DuPont
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Mechanism Of Action ◽  
Bacterial Overgrowth ◽  
Gastrointestinal Disorder ◽  
Small Intestinal Bacterial Overgrowth ◽  
The United States ◽  
Clinical Effects ◽  
Healthy Individuals ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with a multifactorial pathophysiology. The gut microbiota differs between patients with IBS and healthy individuals. After a bout of acute gastroenteritis, postinfection IBS may result in up to approximately 10% of those affected. Small intestinal bacterial overgrowth (SIBO) is more common in patients with IBS than in healthy individuals, and eradication of SIBO with systemic antibiotics has decreased symptoms of IBS in some patients with IBS and SIBO. The nonsystemic (i.e. low oral bioavailability) antibiotic rifaximin is indicated in the United States and Canada for the treatment of adults with IBS with diarrhea (IBS-D). The efficacy and safety of 2-week single and repeat courses of rifaximin have been demonstrated in randomized, placebo-controlled studies of adults with IBS. Rifaximin is widely thought to exert its beneficial clinical effects in IBS-D through manipulation of the gut microbiota. However, current studies indicate that rifaximin induces only modest effects on the gut microbiota of patients with IBS-D, suggesting that the efficacy of rifaximin may involve other mechanisms. Indeed, preclinical data reveal a potential role for rifaximin in the modulation of inflammatory cytokines and intestinal permeability, but these two findings have not yet been examined in the context of clinical studies. The mechanism of action of rifaximin in IBS is likely multifactorial, and further study is needed.

scholarly journals Clinical Effects and Safety of Tongxieyaofang on Diarrhea Predominant Irritable Bowel Syndrome: A Meta-Analysis of Randomized Trails

2019 ◽  
Vol 2019 ◽  
pp. 1-11
Author(s):  
Yuhong Zhou ◽  
Shutang Han ◽  
Yamin He
Keyword(s):  
Irritable Bowel Syndrome ◽  
Large Scale ◽  
Primary Outcome ◽  
Meta Analysis ◽  
Effective Rate ◽  
Risk Of Bias ◽  
Clinical Effects ◽  
Randomized Controlled ◽  
Study Results ◽  
Irritable Bowel

Background. Tongxieyaofang (TXYF), a prescription originated from traditional Chinese medicine (TCM), has been widely used on treating Diarrhea Predominant Irritable Bowel Syndrome (IBS-D). The purpose of this meta-analysis was to investigate whether TXYF was effective and safe for IBS-D. Methods. We searched seven electronic databases including CENTRAL, MEDLINE, PubMed, CNKI, VIP, CBM, and Wanfang Data up to 26 July 2017. Randomized controlled trails (RCTs) were eligible, regardless of blinding. Risk of bias of included trials was evaluated according to the Cochrane Handbook. Results. The total number of participants analyzed in the meta-analysis was 3062, of which 1556 received TXYF, while 1506 received ordinary treatment. The primary outcome was clinical effective rate. Compared with conventional medication which included probiotics, pinaverium bromide, trimebutine, and Oryzanol, TXYF significantly improved the clinical effective rate (n=37, OR: 4.61; 95% CI: 3.67–5.78; P < 0.00001) and decreased the adverse events (n=10, OR: 0.26; 95% CI: 0.08–0.86; P = 0.03). There was not significant association with the score of abdominal pain, defecating frequency, fecal property, and total symptom. Conclusions. We suggested a moderate recommendation for TXYF on IBS-D, due to the fact that the risk of bias of the finally included trails was not high. Considering that all identified studies were not of high qualities and large samples, further rigorously designed and large scale RCTs were necessary to improve the applicability of our study results.

scholarly journals Effect of Korean Herbal Medicine Combined with a Probiotic Mixture on Diarrhea-Dominant Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Seok-Jae Ko ◽  
Gajin Han ◽  
Seul-Ki Kim ◽  
Jae-Gu Seo ◽  
Won-Seok Chung ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Herbal Medicine ◽  
Combination Therapy ◽  
Intestinal Microbiota ◽  
Controlled Trial ◽  
Clinical Effects ◽  
Life Changes ◽  
Double Blind ◽  
Treatment Groups ◽  
Irritable Bowel

Introduction. Although combination therapy with herbal medicine and probiotics is gaining popularity for controlling diarrhea-dominant irritable bowel syndrome (D-IBS) symptoms, few studies have investigated its clinical effects.Materials and Methods. Fifty-three patients with D-IBS were randomly allocated into 1 of the following 4 groups: herbal medicine (Gwakhyangjeonggisan; GJS) plus probiotics (Duolac7S; DUO), GJS plus placebo DUO, placebo GJS plus DUO, and placebo GJS plus placebo DUO. The study period consisted of a 2-week run-in, 8 weeks of administration, and 2 weeks of follow-up. The primary outcomes were weekly adequate relief (AR) of overall IBS symptoms and the proportion of responders (PR) during the administration period. The secondary outcomes included individual IBS symptoms, stool assessment, and quality of life. Changes of intestinal microbiota and intestinal permeability were also analyzed.Results and Discussion. Weekly AR was not different among the 4 groups throughout the treatment period. However, the 3 treatment groups exhibited significant improvements in PR compared to the findings in the placebo group. In the intestinal microbiota assessment, herbal medicine and probiotics synergistically increased beneficial bacteria counts.Conclusion. Combination therapy with herbal medicine and probiotics appears to relieve overall IBS symptoms by synergistically increasing beneficial intestinal microbe counts.

scholarly journals Randomized Clinical Trial: The Clinical Effects of Herb-Partitioned Moxibustion in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Yu-xia Ma ◽  
Xiao Liu ◽  
Cun-zhi Liu ◽  
Lin-peng Wang ◽  
Gang Guo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Abdominal Pain ◽  
Adverse Events ◽  
Abdominal Distension ◽  
Clinical Effects ◽  
End Of Treatment ◽  
Significant Difference ◽  
Irritable Bowel

Objective. To explore the efficacy of Herb-partitioned moxibustion in treating IBS-D patients.Method. 210 IBS-D patients were randomly assigned on a3:3:2basis to group HM, group FM, or group PB for 4-week treatment. The change of GSRS total score at weeks 4 and 8, the changes of GSRS specific scores, and adverse events were evaluated.Results. Patients in group HM and group FM had lower GSRS total score at week 4 (1.98±0.303,2.93±0.302versus3.73±0.449) and at week 8 (2.75±0.306,3.56±0.329versus4.39±2.48) as compared with patients’ score in group PB. However, there was no significant difference of GSRS total score between group HM and group FM. The effect of HM was significantly greater than that of orally taking PB in ameliorating the symptoms of rugitus (0.38 versus 0.59,P<0.05), abdominal pain (0.28 versus 0.57,P<0.01), abdominal distension (0.4 versus 0.7,P<0.01), and increased passage of stools (0.06 versus 0.25,P<0.01) at the end of treatment period. In the follow-up period, patients’ therapeutic effect in group HM remained greater than that in group FM (in abdominal pain, abdominal distension, and increased passage of stools) and that in group PB (in loose stools).Conclusions. HM appears to be a promising, efficacious, and well-tolerated treatment for patients with IBS-D.

Modification of gut microbiota as a method of treatment of irritable bowel syndrome (literature review and own data)

2021 ◽  
Author(s):  
S. M. Tkach ◽  
A. E. Dorofeev ◽  
Y. G. Kuzenko
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Sufficient Evidence ◽  
Clinical Effects ◽  
Time Treatment ◽  
Probiotic Strains ◽  
Irritable Bowel ◽  
Specific Symptoms

Recently, our knowledge of gut microbiota (GM) disorders in various pathologies has significantly increased. In particular, to date, there is sufficient evidence that various disorders of GM may play a pathogenetic role in irritable bowel syndrome (IBS). Therefore, various methods of GM modification are now considered as a new promising strategy for the treatment of patients with IBS. The use of probiotics, prebiotics, synbiotics, antibiotics and fecal microbiota transplantation (FMT) are considered as methods of GM modification. Many clinical trials have been conducted to examine the therapeutic effect of probiotics on general or specific symptoms of IBS, but most of these studies have been very heterogeneous. Although some meta‑analyzes or systematic reviews show that probiotics may be useful in treating the symptoms of IBS, their findings in the studies differ due to insufficient sample size, poor study design, and the use of different probiotic strains. Currently, only one selective intestinal antibiotic with eubiotic properties is known — rifaximin, the effectiveness and safety of which have been proven in large randomized trials. The authors presented their own experience of rifaximin use at IBS that confirmed its efficiency. Own experience of the FMT conduction in patients with IBS is also presented. It has been revealed that even one‑time treatment significantly affected the GM by reducing the frequency and severity of dysbiotic disorders; it was accompanied by significant clinical effects in most patients that lasted up to 3 months of follow‑up.

Sign in / Sign up

Export Citation Format

Share Document